New pivotal trial data suggest AstraZeneca will soon be able to compete with PD-1/L1 inhibitor leaders in early-stage non-small cell lung cancer (NSCLC) treatment, but whether its perioperative approach of drug treatment before and after surgery will outshine rivals is yet to be seen.
AstraZeneca Advances In Early Stage Lung Cancer With Imfinzi And Tagrisso
Pursuing Leaders With Double Neoadjuvant/Adjuvant Approach
AstraZeneca’s Imfinzi is playing catch-up to other PD1/L1 targeting agents in neoadjuvant/adjuvant NSCLC with new data from AEGEAN, but new survival data for Tagrisso from ADAURA consolidate its dominance in early-stage EGFR positive disease.
More from Clinical Trials
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
More from R&D
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.